Allogene TherapeuticsNASDAQ: ALLO

Allogene (ALLO) announces lackluster first-quarter 2024 earnings. The company obtains the rights to develop and market its CD19 oncology program in Europe.

Allogene Therapeutics, Inc. (NASDAQ: ALLO) Q1 2024 Earnings Conference Call on May 13, 2024 at 5:00 PM ET with company representatives Christine Cassiano, David Chang, Geoff Parker, and Zachary Roberts, as well as various conference call participants.

Allogene Therapeutics (ALLO) reported a quarterly loss of $0.38 per share, matching the Zacks Consensus Estimate. This is an improvement from the loss of $0.68 per share reported in the same quarter last year.

Investing in future technologies can be a profitable strategy. By identifying trends early, investors can stay ahead of the game and benefit financially.

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.66 per share a year ago.

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Allogene Therapeutics, Inc. (ALLO) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALLO's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.